In the precise world of radiopharmaceuticals, where a radioactive drug must be exactly as potent as the label claims, quality control is a non-negotiable final gate. For a new generation of cancer therapies that use alpha particles to target tumors, verifying that potency has traditionally relied on methods with known blind spots. Lyla Systems, a hardware startup emerging from Delft, is betting that a more direct form of measurement can tighten that final check [Yes!Delft, undated].
A Hardware Wedge into a Regulated Process
Lyla's core proposition is a hardware and software system designed to measure alpha particles directly, in real time, during the quality control process for radiopharmaceuticals [Yes!Delft, undated]. This contrasts with the more common scintillator-based methods, which the company claims can suffer from inaccuracies and blind spots [Yes!Delft, undated]. The bet is that superior measurement fidelity will be a compelling wedge into the highly regulated production workflows of pharmaceutical and radiopharmaceutical companies. For a field where a therapy's efficacy and safety hinge on precise dosing, even marginal improvements in measurement confidence could command a premium.
The Team and Its Academic Roots
The company appears to be a classic deep-tech spinout, rooted in academic research and incubated at the YES!Delft accelerator. Co-founder Ernst van der Wal is described as the original researcher behind the technology, with a background as a creative engineer at TU Delft [LinkedIn, undated] [Yes!Delft, undated]. He is joined by co-founders Bauke van Gameren, who leads software development with prior experience at firms like Tractable, and Kas Hogeboom, who brings business expertise [RocketReach, undated] [Yes!Delft, undated]. This blend of research, software, and commercial focus is a common template for hardware ventures aiming to bridge the lab-to-factory gap. Their progress to date has been supported by a pre-seed investment from Graduate Entrepreneur, though the amount remains undisclosed [Graduate.nl, undated].
| Founder | Role | Key Background |
|---|---|---|
| Ernst van der Wal | Co-founder | Original researcher; creative engineer, TU Delft [LinkedIn, undated] |
| Bauke van Gameren | Co-founder, Software Lead | Previous roles at Primio, Tractable [RocketReach, undated] |
| Kas Hogeboom | Co-founder | Business expertise [Yes!Delft, undated] |
The Road from Prototype to Production Line
The path for any new hardware entering a Good Manufacturing Practice (GMP) environment is steep. Lyla's immediate challenges are the classic ones for an early-stage medtech hardware company.
- Technical validation. The company's claims of superior accuracy need to be demonstrated through peer-reviewed data or third-party verification to gain credibility with regulated manufacturers.
- Regulatory strategy. While the device is for quality control and not directly administered to patients, it will still need to fit within validated QC protocols, which may require its own regulatory filings or extensive customer-led validation.
- Commercial traction. The public record shows no named customers or pilot deployments. Securing a first lighthouse customer in the pharmaceutical industry will be a critical proof point for the technology and the business model. Competition is also well-established. The market for radiopharmaceutical QC equipment includes large, entrenched players like Eckert & Ziegler and Elysia-Raytest, which have deep customer relationships and extensive product portfolios. Lyla's success will depend on proving its technology is not just incrementally better, but fundamentally necessary for the specific demands of alpha-emitting therapies.
The Patient Population at the End of the Line
The ultimate context for Lyla's work is the patient population waiting for these therapies. Targeted alpha therapy (TAT) is an emerging modality for treating cancers like prostate cancer and neuroendocrine tumors, where alpha particles can deliver a highly potent, localized dose of radiation. The current standard of care for QC often involves indirect measurement techniques or complex, multi-step assays that can be time-consuming and potentially less precise. If Lyla's system can reduce uncertainty and speed up release times, it could contribute to more reliable and potentially more accessible treatment batches. For patients, that translates to confidence that the therapy they receive is exactly as potent as intended, a small but critical variable in a difficult fight.
The next twelve months will be telling. The company must move from a promising research project to a tool that can be integrated into a real production suite. Key milestones to watch will be the publication of technical performance data, the announcement of a first industry partnership or pilot, and any movement toward the regulatory clearances that would ease adoption. In a sector where trust is built on data and compliance, Lyla's quiet start is not unusual. But the clock is now ticking to turn its academic promise into industrial proof.
Sources
- [Yes!Delft, undated] Lyla: Quality control for the next generation of cancer treatment | https://yesdelft.com/stories/lyla-quality-control-for-the-next-generation-of-cancer-treatment/
- [Graduate.nl, undated] New pre-seed investment: LYLA | https://www.graduate.nl/insights/new-pre-seed-investment-lyla
- [LinkedIn, undated] Ernst van der Wal - Lyla | https://www.linkedin.com/in/ernstvdwal/
- [RocketReach, undated] Bauke van Gameren Email & Phone Number | https://rocketreach.co/bauke-van-gameren-email_9152128